(RGC) Regencell Bioscience - Ratings and Ratios
Traditional Chinese Medicine, Neurocognitive Disorders, ADHD Treatment, Autism Treatment
| Risk via 10d forecast | |
|---|---|
| Volatility | 179% |
| Value at Risk 5%th | 187% |
| Relative Tail Risk | -36.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.16 |
| Alpha | 996.37 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.268 |
| Beta | -0.194 |
| Beta Downside | -1.362 |
| Drawdowns 3y | |
|---|---|
| Max DD | 93.00% |
| Mean DD | 60.78% |
| Median DD | 73.28% |
Description: RGC Regencell Bioscience November 08, 2025
Regencell Bioscience Holdings Ltd (NASDAQ: RGC) is a Hong Kong-based company that applies Traditional Chinese Medicine (TCM) platforms to develop therapeutics for neurocognitive disorders, with its current pipeline targeting attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The firm was incorporated in 2014 and operates under the biotechnology sub-industry classification.
As of the most recent filing (Q2 2024), Regencell reported a market capitalization of roughly US$ 45 million and held cash and cash equivalents of about US$ 12 million, sufficient to fund its R&D activities through the end of 2025 under current burn-rate assumptions. The lead candidate, a TCM-derived compound for ADHD, is in Phase II clinical testing, while an ASD formulation remains in pre-clinical development.
The company’s growth prospects are tied to several macro-level drivers: (1) an aging global population and rising prevalence of neurodevelopmental disorders, which expands the addressable market; (2) increasing regulatory openness to plant-based and traditional medicine-derived drugs in China and the United States; and (3) heightened investor interest in niche biotech firms that can leverage low-cost R&D pipelines. Conversely, the firm faces execution risk around clinical trial outcomes, potential regulatory hurdles for TCM-based products, and limited scale compared with larger biotech peers.
For a deeper, data-driven assessment of Regencell’s valuation and risk profile, you may find the analyst tools on ValueRay useful for independent research.
RGC Stock Overview
| Market Cap in USD | 6,428m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-07-16 |
| Return 12m vs S&P 500 | 7,422% |
| Analyst Rating | - |
RGC Dividends
Currently no dividends paidRGC Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 178.27% |
| CAGR/Max DD Calmar Ratio | 1.92 |
| CAGR/Mean DD Pain Ratio | 2.93 |
| Current Volume | 111.9k |
| Average Volume | 98.7k |
Piotroski VR‑10 (Strict, 0-10) 1.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA 1.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 (>3.0%) and CFO -2.00m > Net Income -2.78m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 34.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.0m) change vs 12m ago -97.37% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -45.62 (EBITDA TTM -2.69m / Interest Expense TTM -62.4k) >= 6 (WARN >= 3) |
Altman Z'' 3.29
| (A) 0.85 = (Total Current Assets 6.59m - Total Current Liabilities 193.6k) / Total Assets 7.48m |
| (B) -2.89 = Retained Earnings (Balance) -21.6m / Total Assets 7.48m |
| warn (B) unusual magnitude: -2.89 — check mapping/units |
| (C) -0.32 = EBIT TTM -2.84m / Avg Total Assets 8.98m |
| (D) 8.79 = Book Value of Equity 6.72m / Total Liabilities 763.8k |
| Total Rating: 3.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.35
| 1. Piotroski 1.0pt |
| 2. FCF Yield -0.03% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda 1.07 |
| 6. ROIC - WACC (= -42.39)% |
| 7. RoE -37.27% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 23.92% |
What is the price of RGC shares?
Over the past week, the price has changed by -2.92%, over one month by -25.59%, over three months by +2.35% and over the past year by +8313.33%.
Is RGC a buy, sell or hold?
What are the forecasts/targets for the RGC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 13.8 | 9% |
RGC Fundamental Data Overview November 15, 2025
P/B = 1401.4816
Beta = 2.003
Revenue TTM = 0.0 USD
EBIT TTM = -2.84m USD
EBITDA TTM = -2.69m USD
Long Term Debt = 85.7k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 59.8k USD (from shortTermDebt, last fiscal year)
Debt = 85.7k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.88m USD (from netDebt column, last fiscal year)
Enterprise Value = 6.42b USD (6.43b + Debt 85.7k - CCE 7.96m)
Interest Coverage Ratio = -45.62 (Ebit TTM -2.84m / Interest Expense TTM -62.4k)
FCF Yield = -0.03% (FCF TTM -2.00m / Enterprise Value 6.42b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.97m) / Revenue TTM)
Tobins Q-Ratio = 858.4 (set to none) (Enterprise Value 6.42b / Total Assets 7.48m)
Interest Expense / Debt = 4220 % (Interest Expense 3.62m / Debt 85.7k)
Taxrate = -7.15% (negative due to tax credits) (312.1k / -4.36m)
NOPAT = -3.05m (EBIT -2.84m * (1 - -7.15%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 34.02 (Total Current Assets 6.59m / Total Current Liabilities 193.6k)
Debt / Equity = 0.01 (Debt 85.7k / totalStockholderEquity, last quarter 6.72m)
Debt / EBITDA = 1.07 (negative EBITDA) (Net Debt -2.88m / EBITDA -2.69m)
Debt / FCF = 1.44 (negative FCF - burning cash) (Net Debt -2.88m / FCF TTM -2.00m)
Total Stockholder Equity = 7.47m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.21% (Net Income -2.78m / Total Assets 7.48m)
RoE = -37.27% (Net Income TTM -2.78m / Total Stockholder Equity 7.47m)
RoCE = -37.67% (EBIT -2.84m / Capital Employed (Equity 7.47m + L.T.Debt 85.7k))
RoIC = -37.09% (negative operating profit) (NOPAT -3.05m / Invested Capital 8.22m)
WACC = 5.30% (E(6.43b)/V(6.43b) * Re(5.30%) + (debt cost/tax rate unavailable))
Discount Rate = 5.30% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -83.78%
Fair Price DCF = unknown (Cash Flow -2.00m)
EPS Correlation: 23.92 | EPS CAGR: 0.03% | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Additional Sources for RGC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle